Abstract

BackgroundGenetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus (HCV) infection. We investigated the IFNL4 rs12979860 and the PDCD1 polymorphisms in 734 HCV‐positive patients, including 461 cases with liver disease of varying severity and 273 patients with lymphoproliferative disorders to determine the association of these genes with patient's outcome.MethodsExpression levels of PDCD1 mRNA encoded by haplotypes were investigated by quantitative PCR in hepatocellular carcinoma (HCC) tissue and peripheral blood mononuclear cells. Flow cytometry was used to detect PD‐1 and its ligand PD‐L1.ResultsThe frequency of IFNL4 rs12979860 C/T or T/T genotypes was significantly higher in patients with HCV‐related diseases than blood donors (P < .0001). Patients expressing the IFNλ4 variant with one amino acid change that reduces IFNλ4 secretion was found increased in frequency in HCV‐related diseases compared to HCC PDCD1 mRNA levels in HCC tissue were significantly higher in cases carrying the PD‐1.3 A or the PD‐1.7 G allele (P = .0025 and P = .0167). Linkage disequilibrium (LD) between PD‐1.3 and IFNL4 was found in patients with mixed cryoglobulinaemia (MC) only (LD = 0 in HCC; LD = 72 in MC). PBMCs of MC patients expressed low levels of PD‐L1 in CD19+IgM+B cells and of PD‐1 in CD4+T cells suggesting the involvement of regulatory B cell‐T cell interaction to the pathogenesis of MC.ConclusionCollectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV‐related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC.Lay summaryStudies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV‐related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV‐related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD‐L1 on B cells and high PD‐1 on CD4+T‐cells in patients with HCV‐positive cryoglobulinaemia suggests a critical role of the PD‐1/PD‐L1 signaling in modulating B cell‐T cell interaction in this lymphoproliferative disease.

Highlights

  • Individuals with a hepatitis C virus (HCV) infection develop chronic hepatitis C (CHC) or remain asymptomatic

  • Collectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV-related hepatocellular carcinoma (HCC) and an epistatic contribution of Interferon-lambda 4 (IFNL4) and PDCD1 in mixed cryoglobulinaemia (MC)

  • Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age

Read more

Summary

Conclusion

Our data indicate an important contribution of IFNλ4 expression to the development of HCV-related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC. Lay summary: Studies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV-related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD-L1 on B cells and high PD-1 on CD4+T-cells in patients with HCV-positive cryoglobulinaemia suggests a critical role of the PD-1/PD-L1 signaling in modulating B cell-T cell interaction in this lymphoproliferative disease. KEYWORDS cryoglobulinaemia, hepatitis virus C, hepatocellular carcinoma, IFNλ4, PD-1

Findings
| INTRODUCTION
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call